A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients1,2
2003 ◽
Vol 75
(8)
◽
pp. 1404-1408
◽
1987 ◽
Vol 44
(6)
◽
pp. 775-777
◽
1988 ◽
Vol 140
(6)
◽
pp. 1390-1393
◽